[ad_1]
ORLANDO, Fla. — There was drama at the American Association for Cancer Research’s annual meeting: Stocks plummeted, companies launched new compounds and trial results, and a mystery on blood cancer is one step closer to being resolved. If you missed the conference here last week, here are some highlights.
Moderna and Merck have shown the first randomized clinical evidence that their melanoma vaccine mRNA-4157in combination with pembrolizumab, may reduce the risk of relapse for patients, compared to pembrolizumab alone.
|
Sources 2/ https://www.statnews.com/2023/04/20/aacr-highlights-cancer-vaccine-relay-immunotherapy/ The mention sources can contact us to remove/changing this article |
[ad_2]